Literature DB >> 27196773

Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.

Stephen Iwanowycz1, Junfeng Wang1, Johnie Hodge1, Yuzhen Wang1, Fang Yu2, Daping Fan3.   

Abstract

Macrophage infiltration correlates with severity in many types of cancer. Tumor cells recruit macrophages and educate them to adopt an M2-like phenotype through the secretion of chemokines and growth factors, such as MCP1 and CSF1. Macrophages in turn promote tumor growth through supporting angiogenesis, suppressing antitumor immunity, modulating extracellular matrix remodeling, and promoting tumor cell migration. Thus, tumor cells and macrophages interact to create a feedforward loop supporting tumor growth and metastasis. In this study, we tested the ability of emodin, a Chinese herb-derived compound, to inhibit breast cancer growth in mice and examined the underlying mechanisms. Emodin was used to treat mice bearing EO771 or 4T1 breast tumors. It was shown that emodin attenuated tumor growth by inhibiting macrophage infiltration and M2-like polarization, accompanied by increased T-cell activation and reduced angiogenesis in tumors. The tumor inhibitory effects of emodin were lost in tumor-bearing mice with macrophage depletion. Emodin inhibited IRF4, STAT6, and C/EBPβ signaling and increased inhibitory histone H3 lysine 27 tri-methylation (H3K27m3) on the promoters of M2-related genes in tumor-associated macrophages. In addition, emodin inhibited tumor cell secretion of MCP1 and CSF1, as well as expression of surface anchoring molecule Thy-1, thus suppressing macrophage migration toward and adhesion to tumor cells. These results suggest that emodin acts on both breast cancer cells and macrophages and effectively blocks the tumor-promoting feedforward loop between the two cell types, thereby inhibiting breast cancer growth and metastasis. Mol Cancer Ther; 15(8); 1931-42. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27196773      PMCID: PMC4975665          DOI: 10.1158/1535-7163.MCT-15-0987

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  50 in total

1.  PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.

Authors:  Joao Incio; Josh Tam; Nuh N Rahbari; Priya Suboj; Dan T McManus; Shan M Chin; Trupti D Vardam; Ana Batista; Suboj Babykutty; Keehoon Jung; Anna Khachatryan; Tai Hato; Jennifer A Ligibel; Ian E Krop; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Masabumi Shibuya; Peter Carmeliet; Raquel Soares; Dan G Duda; Rakesh K Jain; Dai Fukumura
Journal:  Clin Cancer Res       Date:  2016-02-09       Impact factor: 12.531

2.  Emodin inhibits ATP-induced IL-1β secretion, ROS production and phagocytosis attenuation in rat peritoneal macrophages via antagonizing P2X₇ receptor.

Authors:  Shuyan Zhu; Yuxiang Wang; Xinyu Wang; Junying Li; Fen Hu
Journal:  Pharm Biol       Date:  2013-09-12       Impact factor: 3.503

3.  Sustained enhanced growth of carcinoma EO771 in C57 black mice.

Authors:  A E CASEY; W R LASTER; G L ROSS
Journal:  Proc Soc Exp Biol Med       Date:  1951-06

4.  Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation.

Authors:  Tatsuya Kaneshiro; Takamitsu Morioka; Morihiko Inamine; Tatsuya Kinjo; Junya Arakaki; Itaru Chiba; Nao Sunagawa; Masumi Suzui; Naoki Yoshimi
Journal:  Eur J Pharmacol       Date:  2006-09-23       Impact factor: 4.432

5.  A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.

Authors:  Ying Zheng; Hongwei Qin; Stuart J Frank; Luqin Deng; David W Litchfield; Ayalew Tefferi; Animesh Pardanani; Fang-Tsyr Lin; Jingzhi Li; Bingdong Sha; Etty N Benveniste
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

6.  Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.

Authors:  Juan Li; Peishu Liu; Hongluan Mao; Ancong Wanga; Xiaolei Zhang
Journal:  Oncol Rep       Date:  2009-06       Impact factor: 3.906

7.  Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor.

Authors:  Akihiro Muto; Mayumi Hori; Yosuke Sasaki; Akari Saitoh; Iho Yasuda; Tadahito Maekawa; Tomoe Uchida; Keiko Asakura; Tomonori Nakazato; Toshio Kaneda; Masahiro Kizaki; Yasuo Ikeda; Tadashi Yoshida
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

8.  A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis.

Authors:  Shicheng Su; Qiang Liu; Jingqi Chen; Jianing Chen; Fei Chen; Chonghua He; Di Huang; Wei Wu; Ling Lin; Wei Huang; Jin Zhang; Xiuying Cui; Fang Zheng; Haiyan Li; Herui Yao; Fengxi Su; Erwei Song
Journal:  Cancer Cell       Date:  2014-05-12       Impact factor: 31.743

Review 9.  Harnessing the antitumor potential of macrophages for cancer immunotherapy.

Authors:  Kristen B Long; Gregory L Beatty
Journal:  Oncoimmunology       Date:  2013-11-04       Impact factor: 8.110

10.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Authors:  Debbie C Strachan; Brian Ruffell; Yoko Oei; Mina J Bissell; Lisa M Coussens; Nancy Pryer; Dylan Daniel
Journal:  Oncoimmunology       Date:  2013-12-04       Impact factor: 8.110

View more
  29 in total

1.  Anticancer activity of emodin is associated with downregulation of CD155.

Authors:  Liang Fang; Fang Zhao; Stephen Iwanowycz; Junfeng Wang; Sophia Yin; Yuzhen Wang; Daping Fan
Journal:  Int Immunopharmacol       Date:  2019-07-17       Impact factor: 4.932

2.  Intraductal Adaptation of the 4T1 Mouse Model of Breast Cancer Reveals Effects of the Epithelial Microenvironment on Tumor Progression and Metastasis.

Authors:  Huda I Atiya; Anna Dvorkin-Gheva; John Hassell; Shrusti Patel; Rachel L Parker; Adam Hartstone-Rose; Johnie Hodge; Daping Fan; Ann F Ramsdell
Journal:  Anticancer Res       Date:  2019-05       Impact factor: 2.480

3.  Emodin reduces tumor burden by diminishing M2-like macrophages in colorectal cancer.

Authors:  Alexander T Sougiannis; Brandon VanderVeen; Ioulia Chatzistamou; Jason L Kubinak; Mitzi Nagarkatti; Daping Fan; E Angela Murphy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-01-12       Impact factor: 4.052

Review 4.  The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.

Authors:  Qing Zhang; Wen Wen Chen; Xue Sun; Die Qian; Dan Dan Tang; Li Lin Zhang; Mei Yan Li; Lin Yu Wang; Chun-Jie Wu; Wei Peng
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

Review 5.  Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin.

Authors:  Esra Küpeli Akkol; Iffet Irem Tatlı; Gökçe Şeker Karatoprak; Osman Tuncay Ağar; Çiğdem Yücel; Eduardo Sobarzo-Sánchez; Raffaele Capasso
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 6.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

7.  Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B.

Authors:  Jiao Yin; Xiansheng Zhao; Xuejiao Chen; Guanxin Shen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

8.  Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients.

Authors:  Yu Mao; Jian Hao; Zi-Qi Jin; Yang-Yang Niu; Xue Yang; Dan Liu; Rui Cao; Xiong-Zhi Wu
Journal:  Oncotarget       Date:  2017-04-18

9.  In vivo murine breast cancer targeting by magnetic iron nanoparticles involving L. GG cytoplasmic fraction.

Authors:  Salar Mokriani; Amir Tukmechi; Naser Harzandi; Leila Jabalameli
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

10.  A New Immunosuppressive Molecule Emodin Induces both CD4+FoxP3+ and CD8+CD122+ Regulatory T Cells and Suppresses Murine Allograft Rejection.

Authors:  Feifei Qiu; Huazhen Liu; Chun-Ling Liang; Golay D Nie; Zhenhua Dai
Journal:  Front Immunol       Date:  2017-11-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.